CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
10129 ETCTN A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors Adult CIRB - Early Phase Emphasis
10130 ETCTN A phase I study of single agent tazemetostat in subjects with advanced solid tumors and B-cell lymphomas with hepatic dysfunction Adult CIRB - Early Phase Emphasis
10131 ETCTN A Phase 1 Study of AZD8186 in Combination with Docetaxel in patients with PTEN mutated or PIK3CB mutated advanced solid tumors, potentially amenable to docetaxel Adult CIRB - Early Phase Emphasis
10132 ETCTN A Phase I Study of the Wee 1 kinase (Wee 1) inhibitor AZD1775 in combination with Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735) Adult CIRB - Early Phase Emphasis
10136 ETCTN A Phase 2 Study Of AZD1775, A WEE1 Inhibitor, In Patients With CCNE1 Amplification Adult CIRB - Early Phase Emphasis
10139 ETCTN A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma Adult CIRB - Early Phase Emphasis
10144 ETCTN A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma with DNA-Repair Defects Adult CIRB - Early Phase Emphasis
10145 ETCTN Phase 1b Study Of Copanlisib In Combination With Nivolumab Or With Nivolumab And Iplimumab Adult CIRB - Early Phase Emphasis
10146 ETCTN Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) + tremelimumab in patients with metastatic triple negative breast cancer Adult CIRB - Early Phase Emphasis
10147 ETCTN A Phase II randomized study of topotecan/carboplatin with or without veliparib in advanced myeloproliferative disorders and chronic myelomonocytic leukemia (CMML). Adult CIRB - Early Phase Emphasis